+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Corneal collagen crosslinking with riboflavin and ultraviolet A to treat induced keratectasia after laser in situ keratomileusis.

      Journal of Cataract and Refractive Surgery

      Adult, Astigmatism, surgery, Collagen, metabolism, Cornea, Corneal Diseases, drug therapy, etiology, Dilatation, Pathologic, prevention & control, Female, Humans, Iatrogenic Disease, Keratomileusis, Laser In Situ, adverse effects, Male, Myopia, Photochemotherapy, Photosensitizing Agents, therapeutic use, Riboflavin, Ultraviolet Rays

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          To determine whether riboflavin and ultraviolet-A (UVA) corneal crosslinking can be used as an alternative therapy to prevent the progression of keratectasia. Institute for Refractive and Ophthalmic Surgery, Zurich, Switzerland, and a private clinic, Athens, Greece. Corneal crosslinking was performed in 10 patients with formerly undiagnosed forme fruste keratoconus or pellucid marginal corneal degeneration who had laser in situ keratomileusis (LASIK) for myopic astigmatism and subsequently developed iatrogenic keratectasia. Surgery was performed in 1 eye per patient. Crosslinking induced by riboflavin and UVA arrested and/or partially reversed keratectasia over a postoperative follow-up of up to 25 months as demonstrated by preoperative and postoperative corneal topography and a reduction in maximum keratometric readings. Riboflavin-UVA corneal crosslinking increased the biomechanical stability of the cornea and may thus be a therapeutic means to arrest and partially reverse the progression of LASIK-induced iatrogenic keratectasia.

          Related collections

          Author and article information



          Comment on this article